Pharmaceutical company Bridge Therapeutics revealed on Tuesday the addition of Edward J. Minskoff to its board of directors.
Currently, Minskoff is a member of NYU Langone Medical Center, Trustee, NYU Langone Medical Center, Finance Committee Member, vice chair of NYU School of Medicine Foundation's Board of Trustees, NYU Cancer Institute's Board of Directors and NYU Real Estate Institute's Advisory Board.
Minskoff is also a member of Columbia University Graduate School of Architecture and Planning, Real Estate Development advisory board; Real Estate Board of New York, Governor; The Real Estate Roundtable's board of directors; Realty Foundation of New York, Director; Partnership for New York City, Board Member; Association of Builders and Owners; Urban Land Institute, Mixed/Use Council; Metropolitan Museum of Art, Real Estate Council; Metropolitan Museum of Art, Friends of Modern Art, Founding Member; and Lincoln Center for the Performing Arts, Steering Committee.
According to the company, Minskoff brings to the board decades of financial and business experience. He is known for his philanthropy work in NYU Medical Center, as well as being involved in numerous cultural and educational institutions, including Columbia University and his alma mater, Michigan State University.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories